Biocon Ltd banner

Biocon Ltd
BSE:532523

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
BSE:532523
Watchlist
Price: 416.8 INR 0.66% Market Closed
Market Cap: ₹499B

Wall St Price Targets

BIOCON Price Targets Summary
Biocon Ltd

Wall Street analysts forecast BIOCON stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIOCON is 426.07 INR with a low forecast of 329.22 INR and a high forecast of 531.24 INR.

Lowest Forecast
Price Target
329.22 INR
21% Downside
Average Forecast
Price Target
426.07 INR
2% Upside
Highest Forecast
Price Target
531.24 INR
27% Upside
Biocon Ltd Competitors:
Price Targets
CALM
Cal-Maine Foods Inc
13% Upside
PTEN
Patterson-UTI Energy Inc
19% Upside
VERK
Verkkokauppa.com Oyj
8% Upside
PTGX
Protagonist Therapeutics Inc
10% Upside

Revenue
Forecast

17% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
17% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 4 years is 13%.

Gross Profit
Forecast

19% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
19% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 19%. The projected CAGR for the next 4 years is 14%.

Operating Income
Forecast

12% / Year
Past Growth
23% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
12% / Year
Past Growth
23% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

Over the last 13 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 4 years is 23%.

Pre-Tax Income
Forecast

13% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
13% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 16%.

Net Income
Forecast

9% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
9% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 4 years is 21%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is BIOCON's stock price target?
Price Target
426.07 INR

According to Wall Street analysts, the average 1-year price target for BIOCON is 426.07 INR with a low forecast of 329.22 INR and a high forecast of 531.24 INR.

What is the Revenue forecast for Biocon Ltd?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 4 years is 13%.

What is the Gross Profit forecast for Biocon Ltd?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 19%. The projected CAGR for the next 4 years is 14%.

What is the Operating Income forecast for Biocon Ltd?
Projected CAGR
23%

Over the last 13 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 4 years is 23%.

What is the Pre-Tax Income forecast for Biocon Ltd?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 16%.

What is the Net Income forecast for Biocon Ltd?
Projected CAGR
21%

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 4 years is 21%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett